


**Amendments to the Specification:**

On Page 1, on the first line following the title, please add:

This application is filed pursuant to 35 U.S.C. § 371 as a United States National Phase Application of International Application No. PCT/US2005/012337 filed April 12, 2005, which claims priority from US 60/563,285 filed April 16, 2004 and US 60/605,288 filed August 27, 2004.

On Page 14, lines 13 – 26, replace the existing paragraph with the following:

In one embodiment, the compound of formula I is a compound of formula I<sup>a</sup>



or a salt, solvate, or physiologically functional derivative thereof, wherein

Q<sub>3</sub> is A<sup>1</sup> when Q<sub>2</sub> is A<sup>2</sup> and Q<sub>3</sub> is A<sup>2</sup> when Q<sub>2</sub> is A<sup>1</sup>;

wherein

A<sup>1</sup> is hydrogen, halogen, C<sub>1-3</sub> alkyl, and

A<sup>2</sup> is the group defined by  $-(Z)_m-(Z^1)-(Z^2)$ , wherein

Z is CH<sub>2</sub> and m is 0, 1, 2, or 3;



Z<sup>1</sup> is S(O)<sub>2</sub>, S(O), or C(O); and

Z<sup>2</sup> is C<sub>1-4</sub> alkyl, or NR<sup>3</sup>R<sup>4</sup>; and

$R^3$  and  $R^4$  are each independently selected from hydrogen, or  $C_{1-4}$  alkyl.

On Page 14, lines 27 – 28, and Page 15, lines 1- 4, replace the existing paragraph with the following:

In a preferred embodiment, the compound of formula I is a compound of formula I<sup>b</sup>



(I)<sup>b</sup>

or a salt, solvate or physiological functional derivative thereof.